These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 11122730)
21. What is new in the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic risk in adults? Virani SS Tex Heart Inst J; 2014 Jun; 41(3):304-5. PubMed ID: 24955047 [No Abstract] [Full Text] [Related]
22. Powdered red yeast rice and plant stanols and sterols to lower cholesterol. Feuerstein JS; Bjerke WS J Diet Suppl; 2012 Jun; 9(2):110-5. PubMed ID: 22531006 [TBL] [Abstract][Full Text] [Related]
23. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs. Alla VM; Agrawal V; DeNazareth A; Mohiuddin S; Ravilla S; Rendell M Drugs; 2013 Jul; 73(10):1025-54. PubMed ID: 23754124 [TBL] [Abstract][Full Text] [Related]
24. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Matsuzaki M; Kita T; Mabuchi H; Matsuzawa Y; Nakaya N; Oikawa S; Saito Y; Sasaki J; Shimamoto K; Itakura H; Circ J; 2002 Dec; 66(12):1087-95. PubMed ID: 12499611 [TBL] [Abstract][Full Text] [Related]
25. [Secondary prevention of recurrent stroke by lowering cholesterol levels and blood pressure]. Stalenhoef AF Ned Tijdschr Geneeskd; 2006 Sep; 150(39):2127-30. PubMed ID: 17059084 [TBL] [Abstract][Full Text] [Related]
26. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study. Paragh G; Márk L; Zámolyi K; Pados G; Ofner P Clin Drug Investig; 2007; 27(9):647-60. PubMed ID: 17705573 [TBL] [Abstract][Full Text] [Related]
27. Low-density lipoprotein cholesterol lowering for the prevention of cardiovascular outcomes in patients with ischemic stroke. Ntaios G; Milionis H Int J Stroke; 2019 Jul; 14(5):476-482. PubMed ID: 31092149 [TBL] [Abstract][Full Text] [Related]
29. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058 [TBL] [Abstract][Full Text] [Related]
30. Low cholesterol level associated with severity and outcome of spontaneous intracerebral hemorrhage: Results from Taiwan Stroke Registry. Chen YW; Li CH; Yang CD; Liu CH; Chen CH; Sheu JJ; Lin SK; Chen AC; Chen PK; Chen PL; Yeh CH; Chen JR; Hsiao YJ; Lin CH; Hsu SP; Chen TS; Sung SF; Yu SC; Muo CH; Wen CP; Sung FC; Jeng JS; Hsu CY; PLoS One; 2017; 12(4):e0171379. PubMed ID: 28422955 [TBL] [Abstract][Full Text] [Related]
31. The evolving role of statins in the management of atherosclerosis. Vaughan CJ; Gotto AM; Basson CT J Am Coll Cardiol; 2000 Jan; 35(1):1-10. PubMed ID: 10636252 [TBL] [Abstract][Full Text] [Related]
32. Underutilization of measurement of serum low-density lipoprotein cholesterol levels and of lipid-lowering therapy in older patients with manifest atherosclerotic disease. Mendelson G; Aronow WS J Am Geriatr Soc; 1998 Sep; 46(9):1128-31. PubMed ID: 9736107 [TBL] [Abstract][Full Text] [Related]
34. Low cholesterol, statins and outcomes in patients with first-ever acute ischemic stroke. Koton S; Molshatzki N; Bornstein NM; Tanne D Cerebrovasc Dis; 2012; 34(3):213-20. PubMed ID: 23006641 [TBL] [Abstract][Full Text] [Related]
35. Pro and con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management. Pedersen TR Am J Cardiol; 2001 Mar; 87(5A):8B-12B. PubMed ID: 11256850 [TBL] [Abstract][Full Text] [Related]
36. [Beyond cholesterol levels: new therapeutic indications of statins]. De Luca N Recenti Prog Med; 2001; 92(7-8):429-32. PubMed ID: 11475783 [TBL] [Abstract][Full Text] [Related]
38. Low-density lipoprotein-cholesterol lowering in individuals at intermediate cardiovascular risk: Percent reduction or target level? Cesena FHY; Laurinavicius AG; Valente VA; Conceição RD; Santos RD; Bittencourt MS Clin Cardiol; 2018 Mar; 41(3):333-338. PubMed ID: 29574925 [TBL] [Abstract][Full Text] [Related]
39. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up. Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913 [TBL] [Abstract][Full Text] [Related]